{"title":"Development of a Discriminatory Drug Dissolution Method for Estimation of Rivaroxaban from Rivaroxaban Tablets","authors":"M. Pankaj","doi":"10.9734/bpi/caprd/v2/4632f","DOIUrl":null,"url":null,"abstract":"Purpose: The objective of the present study is to develop discriminatory dissolution method to be used as a release parameter for testing and evaluating product performance by using quality by design trials intended for regulated markets. Methods: The appropriate conditions were determined after testing solubility in dissolution medium, surfactant concentration, rotation speed, pH of the dissolution medium, apparatus type. Results: Based on studies, the best dissolution conditions were achieved using a USP apparatus II, 900 ml of medium of 0.4% SLS in pH 4.5 acetate buffer at a rotation speed of 75 rpm. Conclusion: This study demonstrates the systematic development of a discriminatory dissolution method for Rivaroxaban, a BCS Class 2 drug exhibiting pH-independent solubility. The dissolution method presented here can be used as a quality control test for Rivaroxaban tablet with special emphasis to understand in a batch to batch evaluation.","PeriodicalId":10848,"journal":{"name":"Current Aspects in Pharmaceutical Research and Development Vol. 2","volume":"236 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Aspects in Pharmaceutical Research and Development Vol. 2","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/bpi/caprd/v2/4632f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The objective of the present study is to develop discriminatory dissolution method to be used as a release parameter for testing and evaluating product performance by using quality by design trials intended for regulated markets. Methods: The appropriate conditions were determined after testing solubility in dissolution medium, surfactant concentration, rotation speed, pH of the dissolution medium, apparatus type. Results: Based on studies, the best dissolution conditions were achieved using a USP apparatus II, 900 ml of medium of 0.4% SLS in pH 4.5 acetate buffer at a rotation speed of 75 rpm. Conclusion: This study demonstrates the systematic development of a discriminatory dissolution method for Rivaroxaban, a BCS Class 2 drug exhibiting pH-independent solubility. The dissolution method presented here can be used as a quality control test for Rivaroxaban tablet with special emphasis to understand in a batch to batch evaluation.